Multidisciplinary CA LEMS Care Models in Small Cell Lung Cancer: Workflows, Treatment Outcomes, Evidence Gaps, and Closing Pearls

Dr. Primdahl describes optimal multidisciplinary CA LEMS care models. Academic and community settings will differ in structure but should share the same goals. At Northwestern, she co-directs a paraneoplastic and immune toxicity clinic that provides rapid-access evaluation and prospective data collection, a model that also enables multi-institutional collaboration needed to build evidence in a rare condition. Key principles are avoiding clinical silos, maintaining a low threshold for specialist-to-specialist communication, and building order sets that facilitate rather than replace critical clinical thinking. Bundled VGCC testing and neurology referral orders, triggered by SCLC diagnosis plus relevant symptom coding, reduce friction in the workflow.

Dr. Sen emphasizes that the optimal system is one where everyone on the team thinks about CA LEMS, not just one designated person. Tumor boards are underused venues for flagging patients with SCLC and unexplained weakness. Borderline or positive VGCC results must be treated as critical lab values requiring proactive outreach rather than passive electronic health record posting. Three structured questions at every SCLC clinic visit can catch cases without adding substantial visit time: can you rise from a chair without your arms? Is your mouth dry? Are you walking less?

With effective treatment, patients can experience stabilization or meaningful improvement in proximal strength, walking endurance, and autonomic symptoms. Untreated CA LEMS risks progressive functional decline, falls, muscle atrophy, and reduced ability to receive cancer-directed therapy. Optimizing LEMS symptoms with amifampridine improves performance status and expands treatment eligibility.

Closing pearls: Dr. Sen urges community oncologists not to overthink VGCC testing; it is a standard blood draw requiring no neurology sign-off first. The most common error is interpreting antibody results as binary; titers do not correlate with severity, seronegative cases are real, and results must always be read alongside clinical findings and electrophysiology. Building a multidisciplinary pathway does not require a mature program on day 1. One reliable trigger point and one neurology contact is enough to start. Dr. Primdahl reinforces the low threshold for testing and referral, adding a critical message: patients with CA LEMS and SCLC consistently show better outcomes than those with de novo SCLC without paraneoplastic syndrome. This should not prompt therapeutic nihilism; it should prompt oncologists to identify and treat CA LEMS so these patients can receive the cancer-directed therapies they stand to benefit from.